Update on PBS Approval for Use of Ovidrel in Males

Ovidrel will now receive PBS subsidy for specific uses in males, as of 1 July 2023.

As outlined on the Healthy Male website, the PBS subsidy is approved for the following applications of Ovidrel in males:

• Treatment of acquired hypogonadotrophic hypogonadism in adulthood
• Puberty induction in males with congenital hypogonadotrophic hypogonadism
• Promotion of testicular descent not due to anatomic obstruction
• Stimulation of spermatogenesis in infertility caused by hypogonadotrophic hypogonadism.

USANZ has supported the Healthy Male organisation in their advocacy efforts to achieve this outcome. 

For further information on this update, please read the Healthy Male article.